Clinical Trials
51 trialsDose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
M.D. Anderson Cancer Center
ALPHA3
Allogene Therapeutics
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
ROTATE
Yale University
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Dana-Farber Cancer Institute
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Amgen
PREDICT-RD
UNC Lineberger Comprehensive Cancer Center
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
Dartmouth-Hitchcock Medical Center
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
Stanford University
PALAVY
Abramson Cancer Center at Penn Medicine
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Masonic Cancer Center, University of Minnesota
FLAMINGO-01
Greenwich LifeSciences, Inc.
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
Second Xiangya Hospital of Central South University
MiRaDoR
MedSIR
Relugolix + Enzalutamide Study in High-Risk Prostate Cancer
University of Oklahoma
CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Peking University People's Hospital
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Dana-Farber Cancer Institute
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
Columbia University
Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
University of Alabama at Birmingham
FIL_GAZEBO
Fondazione Italiana Linfomi - ETS
S101MRD
Peking University People's Hospital
NeckTAR-IN
Centre Jean Perrin
HTLP-ONCO
Assistance Publique - Hôpitaux de Paris
UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
Baylor College of Medicine
GOLD
University of Rochester
Modified Vaccine for High Risk or Low Residual Melanoma Patients
Hadassah Medical Organization
VERDI
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
MRD-positive AML Clinical Study
Institute of Hematology & Blood Diseases Hospital, China
DARA_T_ALL
Tata Memorial Centre
EpLCART
Peter MacCallum Cancer Centre, Australia
Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation
First Affiliated Hospital of Zhejiang University
Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
Ruijin Hospital
Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer
Peking University People's Hospital
Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL
Hospital Universitario Dr. Jose E. Gonzalez
VINCENT
Technische Universität Dresden
CLAUDIA
Seoul National University Hospital
Risk Stratification and MRD-driven Maintenance for MM After ASCT
Peking University People's Hospital
DECIPHER
University of Southampton
Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
Institute of Hematology & Blood Diseases Hospital, China
MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
Beijing 302 Hospital
MRD Response-adapted Allo-HSCT for Adverse-risk AML
Peking University People's Hospital
TRINITY
Gruppo Oncologico del Nord-Ovest
DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
A Study of Chidamide With AZA in MRD Positive AML After Transplant
Guangdong Provincial People's Hospital
SURPASS
Sun Yat-sen University
Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults
PETHEMA Foundation